When will Seladelpar be officially available for sale in China?

As of now, Seladelpar (Seladelpar) has not yet received official marketing approval in China. The drug was developed by Gilead Sciences in the United States and is mainly used to treat patients with primary biliary cholangitis (PBC), especially those who have poor response to treatment with uruxodeoxycholic acid (ursodeoxycholic acid, UDCA). Globally, Siladepa has completed multiple clinical trials and received marketing approval in some countries and regions.

In China, the launch of Siladepa is relatively slow. There is currently no public information showing that Gilead has submitted a marketing application for Siladepa to the China National Medical Products Administration (NMPA). According to China's drug review and approval process, after a new drug is submitted for marketing, it usually needs to go through multiple links such as review of clinical trial data, evaluation of drug quality control standards, and review of drug instructions. The entire process may take several years.

In addition, the listing of Siladepa in the Chinese market still faces certain challenges. First, the incidence of primary biliary cholangitis is relatively low in China, resulting in a limited number of patients with this disease, which may affect the market demand for drugs. Secondly, existing treatment options, such as uruglustat, have been widely used in China, and their efficacy is relatively stable, which may affect patients' acceptance of new drugs.

Nonetheless, as China pays more attention to rare diseases and liver diseases, and continues to optimize the approval process for innovative drugs, the possibility of Siladepa being launched in China in the future still exists. However, the specific launch time still needs to wait for further communication and approval between Gilead and the Chinese drug regulatory authorities.

In short, the marketing process of Siladepa in China has not yet been clarified, and patients and medical staff should pay attention to the latest announcements and information from relevant departments. In the meantime, existing treatment options remain the main options for patients with primary biliary cholangitis. For patients in need, it is recommended to consult with a professional doctor to learn about the latest treatment trends and feasible treatment options.

Reference materials:https://www.drugs.com/donanemab.html